发明名称 |
Un metodo para tratar a un sujeto que tenga cancer que comprende administrar 1-(1(4-metil-5-(2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il)-tiazol-2-il)-amida) de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico en un sujeto que tenga una glutamina en la posicion 859 de la subunidad catalitica p110alfa de pi3k. |
摘要 |
<p>The present invention relates to selective cancer treatment regimes based on assaying for the presence or absence of a glutamine or a nucleic acid that encodes glutamine at position 859 of the catalytic p110αsubunit of PI3K; methods for producing a transmittable form of information for predicting the responsiveness of patient to (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or a pharmaceutically acceptable salt thereof; and a kit thereof.</p> |
申请公布号 |
CL2014002576(A1) |
申请公布日期 |
2015.01.23 |
申请号 |
CL20140002576 |
申请日期 |
2014.09.26 |
申请人 |
NOVARTIS AG. |
发明人 |
FURET PASCAL;FRITSCH CHRISTINE;MARIA SAUVEUR MICHEL |
分类号 |
A61K31/4439 |
主分类号 |
A61K31/4439 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|